Name: 글로벌 시장 동향
SKU: PH7196
Availability: InStock

보고서 요약(국문)

개요
전 세계 루푸스 신염 치료 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
루푸스 신염은 전신성 루푸스 홍반증으로 인해 발생하는 신장 질환의 일종입니다. 루푸스는 자가면역 질환으로, 신체의 면역 체계가 자신의 세포와 장기를 공격하는 질병입니다. 루푸스로 인한 신장 질환은 시간이 지남에 따라 더욱 악화되어 신부전으로 이어질 수 있습니다. 루푸스 신염의 증상으로는 거품뇨와 부종이 있으며, 부종은 체내에 체액이 과다하게 축적되어 다리, 발, 발목에 자주 발생하고 때로는 손이나 얼굴에도 나타날 수 있습니다. 환자는 고혈압이 발생할 수도 있습니다.
루푸스 신염 관리의 주요 목적은 만성 신장 질환(CKD)을 예방하는 것입니다. 기존 치료법은 신장 기능의 완전한 회복을 보장하지 못하며, 질병의 퇴행, 만성 신장 질환(CKD), 그리고 말기 신부전으로의 진행을 막지 못합니다. 미국 루푸스 재단에 따르면, 미국에서는 약 150만 명이 루푸스를 앓고 있으며, 이 중 최대 60%가 루푸스 신염을 앓는 것으로 추정됩니다.
시장 동향: 성장 동인 및 제약 요인
제품 승인 증가
루푸스 신염 치료제 승인이 증가함에 따라 예측 기간 동안 세계 시장 성장이 촉진될 것으로 예상됩니다. 예를 들어, 2021년 1월 오리니아(Aurinia)는 전신성 루푸스로 인한 신장 염증인 루푸스 신염 치료제 루프키니스(Lupkynis, 보클로스포린)에 대해 FDA 승인을 처음으로 획득했습니다.

또한, 2023년 2월 GSK plc는 전신 경화증 치료 가능성을 인정받아 B세포 억제 단일클론 항체인 벤리스타(벨리무맙)에 대해 미국 식품의약국(FDA)으로부터 희귀의약품 지정(ODD)을 획득했습니다. 벤리스타(벨리무맙)는 B림프구 자극인자(BLyS) 특이적 억제제로, 전신성 루푸스(SLE) 및 루푸스 신염(LN)과 같은 전신 자가면역 질환 환자에서 증가하는 것으로 알려진 가용성 BLyS에 결합합니다.
더욱이, 루푸스 신염에 대한 인식 증가, 시장 개발, 연구 투자 및 활동 증가는 예측 기간 동안 세계 시장 성장을 견인할 것으로 예상됩니다.

엄격한 규제 당국
의약품 승인에 대한 엄격한 규제 당국의 요구는 세계 시장 성장을 저해할 것으로 예상됩니다. 또한, 높은 신약 개발 비용과 치료 부작용 역시 예측 기간 동안 세계 시장 성장을 저해하는 요인으로 작용할 것으로 예상됩니다.

시장 세분화 분석
전 세계 루푸스 신염 치료 시장은 치료 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
줄기세포 치료, 시장 주도 예상
줄기세포 치료에 대한 규제 승인이 증가함에 따라 해당 부문의 성장이 촉진되어 예측 기간 동안 전 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 중증 자가면역 질환에 대한 새로운 치료법 개발을 목표로 하는 세포 치료 기업인 키버나 테라퓨틱스(Kyverna Therapeutics)는 2023년 6월, 난치성 루푸스 신염(LN) 환자 치료를 위한 KYV-101에 대해 미국 식품의약국(FDA)의 신속심사 지정을 받았습니다. KYV-101은 자가면역 질환 환자에서 자가반응성 B세포를 포함한 B세포를 제거하기 위해 개발된 새로운 항-CD19 키메라 항원 수용체 T세포(CAR T) 치료제입니다.
또한, 2023년 8월, 임상 단계 기업인 아티바 바이오테라퓨틱스(Artiva Biotherapeutics, Inc.)는 유전자 변형되지 않은 제대혈 유래 동종 냉동 보존 NK 세포 치료 후보 물질인 AlloNK(AB-101이라고도 함)에 대해 미국 식품의약국(FDA)으로부터 임상시험용 신약(IND) 지정을 받았습니다. AlloNK는 리툭시맙과 병용하여 활동성 루푸스 신염(LN)을 동반한 전신성 루푸스(SLE) 환자를 치료하는 데 사용됩니다.
지역 분석
북미 지역이 세계 시장을 주도할 것으로 예상됩니다.
북미 지역의 임상 연구 활동 증가로 인해 예측 기간 동안 북미 지역 시장이 세계 시장을 주도하며 성장세를 보일 것으로 예상됩니다. 예를 들어, 2023년 6월 루푸스 테라퓨틱스(Lupus Therapeutics)는 전신성 루푸스 및 루푸스 신염에 대한 실험적 치료제 이알루맙(ianalumab)의 3건의 3상 임상시험을 수행하기 위한 연합체를 구성했습니다.
루푸스 연구 연합(Lupus Research Alliance)의 임상 연구 계열사인 루푸스 테라퓨틱스는 북미 전역의 주요 학술 센터에서 루푸스 임상 연구자 네트워크(LuCIN)를 통해 노바티스 제약(Novartis Pharmaceuticals Corporation)의 임상시험 수행을 지원할 계획입니다.
또한, 2023년 3월 애브비(AbbVie)는 중등도에서 중증의 활동성 전신성 루푸스(SLE) 환자를 대상으로 우파다시티닙(upadacitinib, RINVOQ, 30mg)을 단독으로 또는 브루톤 티로신 키나제 억제제(elsubrutinib, 60mg)와의 병용 요법(ABBV-599)으로 1일 1회 투여하는 2상 연구의 주요 결과를 발표했습니다. 애브비는 루푸스(SLE) 치료제 우파다시티닙의 임상 일정을 3상으로 연장합니다.
COVID-19 영향 분석
COVID-19 팬데믹 기간 동안 류마티스 관절염(RA), 건선성 관절염, 강직성 척추염, 루푸스, 혈관염을 포함한 자가면역 류마티스 질환(ARD) 환자들은 질환 자체 또는 이러한 질환 치료를 위해 처방되는 약물로 인해 면역 체계가 약화되어 COVID-19 감염, 감염 합병증 및 사망 위험이 높아지는 위험 요인을 인지하게 되었습니다.

시장 세분화
치료 유형별
• 약물 치료
o 아캄프로세이트
o 펜톡시필린
o 인플릭시맙
o 벤조디아제핀
o 코르티코스테로이드
o 기타
• 줄기세포 치료
투여 경로별
• 주사제
• 경구제
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 2022년 11월, 오리니아 파마슈티컬스(Aurinia Pharmaceuticals Inc.)는 영국 의약품 및 의료기기 규제청(MHRA)으로부터 루프키니스(LUPKYNIS)의 영국 판매 허가를 획득했습니다. (보클로스포린)은 전신성 루푸스(SLE)의 심각한 합병증인 활동성 루푸스 신염(LN)을 앓는 성인 환자의 치료에 사용됩니다.
• 2023년 8월, 암 및 자가면역 질환 치료를 위한 혁신적인 논리 게이트 기반 키메라 항원 수용체(CAR) T세포 치료법을 개발하는 임상 단계 기업인 ImmPACT Bio USA, Inc.는 활동성, 난치성 전신성 루푸스(SLE) 치료를 위한 이중특이성 CD19/CD20 CAR T세포 치료법인 IMPT-514에 대해 미국 식품의약국(FDA)의 임상시험용 신약(IND) 지정을 받았습니다.

• 2023년 8월, 염증성, 섬유화성 및 자가면역 질환 치료를 위한 혁신적인 자연 살해 T("NKT") 세포 조절제 파이프라인을 보유한 생명공학 기업인 GRI Bio, Inc.는 2023년 7월~8월 매사추세츠주 사우스브리지에서 개최된 FASEB 주최 자가면역 학회(The Autoimmunity Conference)에서 GRI-0803 개발 프로그램의 전임상 데이터를 발표했습니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Aurinia Pharmaceuticals Inc., AstraZeneca, Novartis Ag, Beigene, Ltd., Glaxosmithkline Llc, Equillium, Inc., Kymera Therapeutics, Inc., Remegen Co., Ltd., Immpact Bio Usa Inc. 등이 있습니다.
보고서 구매 이유

• 치료법, 투여 경로, 유통 채널 및 지역별 글로벌 루푸스 신염 치료 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 세그먼트를 포함한 루푸스 신염 치료 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 루푸스 신염 치료 시장 보고서는 약 61개의 표, 56개의 그림, 186페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Lupus Nephritis Treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Lupus nephritis is a kind of kidney disorder induced by systemic lupus erythematosus. Lupus is an autoimmune condition a disease in which the body’s immune system attacks the body’s own cells and organs. Kidney disorders induced by lupus may get more threatening over the period and direct to kidney failure. The signs of lupus nephritis may enclose foamy urine and edema that transpires when the body has excessive fluid, frequently in the legs, feet, or ankles, and sometimes in the hands or face. The patient may even develop high blood pressure.
The primary purpose of managing lupus nephritis is to circumvent chronic kidney disease (CKD). Existing therapy approaches remain inadequate in representations of total renal response, precluding regressions, CKD, and advancement to end-stage kidney disorder. According to the Lupus Foundation of America, roughly 1.5 million individuals in the United States suffer from lupus, and up to 60% of them are estimated to develop lupus nephritis.
Market Dynamics: Drivers & Restraints
Increasing Product Approvals
The increasing drug product approvals to treat lupus nephritis is expected to boost the global market growth during the forecast period. For instance, in January 2021, Aurinia grasped its first FDA authorization for Lupkynis (voclosporin) for the treatment of lupus nephritis, or kidney inflammation induced by systemic lupus erythematosus.
Moreover, in February 2023, GSK plc obtained the US Food and Drug Administration (FDA) Orphan Drug Designation (ODD) to Benlysta (belimumab), a B-cell inhibiting monoclonal antibody, for the potential therapy of systemic sclerosis. Benlysta (belimumab) is a B-lymphocyte stimulator (BLyS) specific inhibitor that attaches to soluble BLyS, which is encountered to be raised in individuals with systemic autoimmune disorders like systemic lupus erythematosus (SLE) and lupus nephritis (LN).
Furthermore, the growing awareness about lupus nephritis, market developments, increase in research investments and activities are also driving the global market growth during the forecast period.
Stringent Regulatory Authorities
The stringent regulatory authorities authorizing the drug treatments are expected to hamper the global market growth. Furthermore, high drug development costs and treatment side effects are also expected to hamper the global market growth in the forecast period.
Segment Analysis
The global lupus nephritis treatment market is segmented based on treatment, route of administration, distribution channel and region.
Stem Cell Therapy Expected to Dominate Market
The increasing regulatory approvals for stem cell therapy are expected to boost the segment growth, dominating the global market in the forecast period. For instance, in June 2023, Kyverna Therapeutics ("Kyverna"), a cell therapy corporation with the mission of engineering a new class of therapies for severe autoimmune disorders, obtained the U.S. Food and Drug Administration (FDA) Fast Track designation for KYV-101 for the therapy of individuals with refractory lupus nephritis (LN). KYV-101 is a novel anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy developed to deplete B cells, including autoreactive B cells, in autoimmune disorder patients
Moreover, in August 2023, Artiva Biotherapeutics, Inc., a clinical-stage corporation obtained the U.S. FDA Investigational New Drug (IND) designation for its AlloNK (also known as AB-101) a non-genetically-modified, cord blood-derived, allogeneic, cryopreserved NK cell therapy candidate, in mixture with rituximab for the treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis (LN).
Geographical Analysis
North America is Expected to Dominate the Global Market
Increasing clinical research activities in North America is expected to boost the regional market growth dominating the global market during the forecast period. For instance, in June 2023 Lupus Therapeutics formed a coalition to conduct three Phase 3 clinical trials testing an experimental therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.
Lupus Therapeutics, the clinical investigation affiliate of the Lupus Research Alliance, intends to assist Novartis Pharmaceuticals Corporation (Novartis) in conducting the trials via the Lupus Clinical Investigators Network (LuCIN) at leading academic centers throughout North America.
Moreover, in March 2023 AbbVie reported topline outcomes from a Phase 2 study of upadacitinib (RINVOQ, 30 mg) delivered independently or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg), once every day in patients with moderately to severely active systemic lupus erythematosus (SLE). AbbVie is extending its clinical schedule of upadacitinib in SLE to Phase 3.
COVID-19 Impact Analysis
During the COVID-19 pandemic, individuals with autoimmune rheumatic diseases (ARDs), including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, lupus, and vasculitis, had learned risk factors that raised their chance of infections, intricacies from infection, and mortality from COVID-19 owing to compromised immune systems linked to their condition or the medications often prescribed to treat these conditions.
Market Segmentation
By Treatment
• Drug Treatment
o Acamprosate
o Pentoxifylline
o Infliximab
o Benzodiazepines
o Corticosteroids
o Others
• Stem Cell Therapy
By Route of Administration
• Injectable
• Oral
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In November 2022, Aurinia Pharmaceuticals Inc. obtained the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Great Britain marketing authorization for LUPKYNIS (Voclosporin) for the treatment of adults with active lupus nephritis (LN), a severe intricacy of systemic lupus erythematosus (SLE).
• In August 2023, ImmPACT Bio USA, Inc., a clinical-stage corporation designing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies to treat cancer and autoimmune disorders, obtained the U.S. Food and Drug Administration (FDA) investigational new drug (IND) designation for IMPT-514, a bispecific CD19/CD20 CAR T therapy for the treatment of active, refractory systemic lupus erythematosus (SLE).
• In August 2023, GRI Bio, Inc., a biotechnology corporation offering an inventive pipeline of Natural Killer T (“NKT”) cell modulators to treat inflammatory, fibrotic and autoimmune disorders, performed a presentation of preclinical data from its GRI-0803 development program at The Autoimmunity Conference hosted by FASEB held in July-August 2023 in Southbridge, MA.
Competitive Landscape
The major global players in the market include Aurinia Pharmaceuticals Inc., AstraZeneca, Novartis Ag, Beigene, Ltd., Glaxosmithkline Llc, Equillium, Inc., Kymera Therapeutics, Inc., Remegen Co., Ltd., And Immpact Bio Usa Inc. among others.
Why Purchase the Report?
• To visualize the global lupus nephritis treatment market segmentation based on treatment, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of lupus nephritis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global lupus nephritis treatment market report would provide approximately 61 tables, 56 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Product Approvals
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Authorities
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. Pipeline Analysis
5.8. PEST Analysis
5.9. SWOT Analysis
5.10. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Drug Treatment*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Acamprosate
7.2.4. Pentoxifylline
7.2.5. Infliximab
7.2.6. Drug Treatment
7.2.7. Acamprosate
7.2.8. Pentoxifylline
7.2.9. Infliximab
7.2.10. Benzodiazepines
7.2.11. Corticosteroids
7.2.12. Others
7.3. Stem Cell Therapy
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Injectable*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Oral
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Aurinia Pharmaceuticals Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. AstraZeneca
12.3. Novartis AG
12.4. Beigene, Ltd.
12.5. Glaxosmithkline Llc
12.6. Equillium, Inc.
12.7. Kymera Therapeutics, Inc.
12.8. Remegen Co., Ltd.
12.9. Immpact Bio Usa Inc.
12.10. Gri Bio, Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Aurinia Pharmaceuticals Inc., 4.	Key Developments, AstraZeneca, Novartis AG, Beigene, Ltd., Glaxosmithkline Llc, Equillium, Inc., Kymera Therapeutics, Inc., Remegen Co., Ltd., Immpact Bio Usa Inc., Gri Bio, Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Lupus Nephritis Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Lupus Nephritis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Lupus Nephritis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Lupus Nephritis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Lupus Nephritis Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Lupus Nephritis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 7 Global Lupus Nephritis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Lupus Nephritis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Lupus Nephritis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Lupus Nephritis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Lupus Nephritis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Lupus Nephritis Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Lupus Nephritis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 14 North America Lupus Nephritis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Lupus Nephritis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Lupus Nephritis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Lupus Nephritis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 18 South America Lupus Nephritis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Lupus Nephritis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Lupus Nephritis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Lupus Nephritis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 22 Europe Lupus Nephritis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Lupus Nephritis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Lupus Nephritis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Lupus Nephritis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Lupus Nephritis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Lupus Nephritis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Lupus Nephritis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Lupus Nephritis Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Lupus Nephritis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Lupus Nephritis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Aurinia Pharmaceuticals Inc.: Overview

Table 33 Aurinia Pharmaceuticals Inc.: Product Portfolio

Table 34 Aurinia Pharmaceuticals Inc.: Key Developments

Table 35 AstraZeneca: Overview

Table 36 AstraZeneca: Product Portfolio

Table 37 AstraZeneca: Key Developments

Table 38 Novartis AG: Overview

Table 39 Novartis AG: Product Portfolio

Table 40 Novartis AG: Key Developments

Table 41 BEIGENE, LTD.: Overview

Table 42 BEIGENE, LTD.: Product Portfolio

Table 43 BEIGENE, LTD.: Key Developments

Table 44 GlaxoSmithKline LLC: Overview

Table 45 GlaxoSmithKline LLC: Product Portfolio

Table 46 GlaxoSmithKline LLC: Key Developments

Table 47 Equillium, Inc.: Overview

Table 48 Equillium, Inc.: Product Portfolio

Table 49 Equillium, Inc.: Key Developments

Table 50 Kymera Therapeutics, Inc.: Overview

Table 51 Kymera Therapeutics, Inc.: Product Portfolio

Table 52 Kymera Therapeutics, Inc.: Key Developments

Table 53 RemeGen Co., Ltd.: Overview

Table 54 RemeGen Co., Ltd.: Product Portfolio

Table 55 RemeGen Co., Ltd.: Key Developments

Table 56 ImmPACT Bio USA Inc.: Overview

Table 57 ImmPACT Bio USA Inc.: Product Portfolio

Table 58 ImmPACT Bio USA Inc.: Key Developments

Table 59 Gri Bio, Inc.: Overview

Table 60 Gri Bio, Inc.: Product Portfolio

Table 61 Gri Bio, Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Lupus Nephritis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 3 Global Lupus Nephritis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Lupus Nephritis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Lupus Nephritis Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Lupus Nephritis Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 7 Drug Treatment Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Stem Cell Therapy Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Global Lupus Nephritis Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 10 Injectable Route of Administration in Global Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Oral Route of Administration in Global Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Global Lupus Nephritis Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 13 Hospital Pharmacies Distribution Channel in Global Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Retail Pharmacies Distribution Channel in Global Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Online Pharmacies Distribution Channel in Global Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Others Distribution Channel in Global Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Global Lupus Nephritis Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 18 North America Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Asia-Pacific Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Europe Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 South America Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Middle East and Africa Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 North America Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 North America Lupus Nephritis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 25 North America Lupus Nephritis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 26 North America Lupus Nephritis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 27 North America Lupus Nephritis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 28 South America Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 South America Lupus Nephritis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 30 South America Lupus Nephritis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 31 South America Lupus Nephritis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 32 South America Lupus Nephritis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 33 Europe Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 34 Europe Lupus Nephritis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 35 Europe Lupus Nephritis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 36 Europe Lupus Nephritis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 37 Europe Lupus Nephritis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 38 Asia-Pacific Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 39 Asia-Pacific Lupus Nephritis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 40 Asia-Pacific Lupus Nephritis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 41 Asia-Pacific Lupus Nephritis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 42 Asia-Pacific Lupus Nephritis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 43 Middle East & Africa Lupus Nephritis Treatment Market Value, 2021-2030 (US$ Million)

Figure 44 Middle East & Africa Lupus Nephritis Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 45 Middle East & Africa Lupus Nephritis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 46 Middle East & Africa Lupus Nephritis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 47 Aurinia Pharmaceuticals Inc.: Financials

Figure 48 AstraZeneca: Financials

Figure 49 Novartis AG: Financials

Figure 50 Beigene, Ltd.: Financials

Figure 51 GlaxoSmithKline LLC: Financials

Figure 52 Equillium, Inc.: Financials

Figure 53 Kymera Therapeutics, Inc.: Financials

Figure 54 RemeGen Co., Ltd.: Financials

Figure 55 ImmPACT Bio USA Inc.: Financials

Figure 56 Gri Bio, Inc.: Financials

세계 루푸스 신염 치료 시장 – 2023-2030

Global Lupus Nephritis Treatment market - 2023-2030